Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Side effects of selegiline (Eldepryl).

C H Waters1

  • 1Department of Neurology, University of Southern California, Los Angeles.

Journal of Geriatric Psychiatry and Neurology
|January 1, 1992
PubMed
Summary

Selegiline (Eldepryl) is a new Parkinson's disease adjunct therapy. Caution is advised, especially for elderly patients, due to observed side effects like urinary retention.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The management of acute intestinal obstruction.

The Nebraska state medical journal·2010
Same author

Epidemiologic study of 203 sibling pairs with Parkinson's disease: the GenePD study.

Neurology·2002
Same author

Genome-wide scan for Parkinson's disease: the GenePD Study.

Neurology·2001
Same author

Advances in managing Parkinson's disease.

Hospital practice (1995)·2001
Same author

Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study.

Movement disorders : official journal of the Movement Disorder Society·2001
Same author

Impaired perception of vocal emotions in Parkinson's disease: influence of speech time processing and executive functioning.

Brain and cognition·2001

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Parkinson's disease management often involves adjunct therapies to levodopa-carbidopa (Sinemet).
  • Selegiline (Eldepryl) is a recently approved adjunct medication for Parkinson's disease.

Observation:

  • An open-label study administered Selegiline to eight Parkinson's disease patients.
  • Particular attention was paid to side effects in elderly patients.

Findings:

  • Selegiline use in Parkinson's patients led to several observed side effects.
  • Urinary retention was a notable side effect, occurring in two male patients.

Implications:

  • The findings suggest Selegiline should be used cautiously in Parkinson's disease patients.
  • Elderly patients may be more susceptible to specific side effects of Selegiline.